In the following video, Fool contributor Maxxwell Chatsko talks with health care analyst Max Macaluso and recaps the latest earnings results from the pharmaceutical industry. These companies each saw healthy gains in operating results and have big upcoming launches, such as Invokana from Johnson & Johnson (NYSE:JNJ) and Eliquis from Pfizer (NYSE:PFE). Nonetheless, investors will need to keep a long-term focus when viewing these complex pharmaceutical giants.
Fool contributor Maxx Chatsko and Max Macaluso, Ph.D. have no position in any stocks mentioned. Check out Maxwell's personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.
The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
